ASTRO 2025: At 10 years, SBRT comparable to surgery for early-stage lung cancer
Study is the first to compare 10-year outcomes from surgery and a specific kind of radiation therapy known as SBRT (also called SABR) in non-small cell lung cancer
Survival outcomes were similar, but the SBRT group had fewer side effects and potentially less financial burden
Study further confirms radiation as an alternative for these patients, even in cases where the cancer is operable
Researchers from Â鶹ӳ» MD Anderson...
Patients receiving anti-cancer treatment near end of life experience higher rates of hospitalization, ED and ICU use, and less utilization of hospice
Patients who receive systemic anti-cancer treatment near end of life are more likely to be hospitalized, go to the intensive care unit or...
Researchers identify enzyme involved in driving neuron differentiation
A new study from Â鶹ӳ» MD Anderson Cancer Center identified an important role for the KMT2D protein in controlling the development...
MD Anderson experts highlight top trends ahead of 2025 ASTRO meeting
Major themes include advances in actionable biomarkers in pancreatic cancer, proton therapy, artificial intelligence and theranostics
MD Anderson researchers will present more than 65 abstracts, including several providing breakthroughs within these themes
Recent advances in radiation oncology have led to shorter treatment times, increased early disease detection, and artificial intelligence applications that continue to improve cancer...
Sugary drinks may increase risk of metastasis in advanced colorectal cancer
Preclinical study provides first direct evidence linking colorectal cancer metastasis to the glucose-fructose blend found in sugar-sweetened...
Digital twin model shows promise for predicting bone metastasis treatment response in prostate and renal cancers
A new study, published in Cancer Research, highlights the development of advanced digital twin models designed to more accurately reflect...
WCLC 2025: Combination therapy achieves durable response in advanced lung cancer patients
KRAS G12C mutations are among the most common drivers of?non-small cell lung cancer (NSCLC), yet first-line targeted therapy options...
WCLC 2025: Bispecific antibody dose shows promising potential for extensive-stage SCLC
Pumitamig is a novel bispecific antibody targeting both the PD-L1 checkpoint and VEGF, a driver of angiogenesis, being studied in patients...
WCLC 2025: Brigatinib with local therapy can potentially improve outcomes for advanced NSCLC
Almost all patients with ALK-rearranged non-small cell lung cancer (NSCLC) end up with an incomplete response to targeted therapy with tyrosine...
WCLC 2025: Innovative ADC therapy shows promise in hard-to-treat small cell lung cancer
Small cell lung cancer (SCLC)?remains one of the most aggressive and difficult-to-treat forms of lung cancer, with few effective therapies...
Novel sequencing technology links DNA and RNA to provide molecular insights into breast cancer progression
Breast cancer often starts in the epithelial cells lining the milk ducts and lobules, but there are many subtypes that make it challenging...
Targeted radiation helps patients with kidney cancer?delay systemic therapy?
Some patients with?clear cell renal cell carcinoma (ccRCC) ¨C the most common type of?kidney cancer?in adults ¨C experience oligometastatic...
Researchers identify predictive biomarkers for oral cancer metastasis
Most oral cancers start in squamous cells lining the mouth and tongue, and frequently metastasize to the lymph nodes. To identify potential...
First-in-class pan-KRAS inhibitor shows strong antitumor activity in preclinical models
KRAS is the most commonly mutated gene in cancer, but targeting the mutant protein is notoriously difficult because current therapies work...